[1] MAURICE J, MANOUSOU P. Non-alcoholic fatty liver disease[J]. Clin Med, 2018, 18(3):245-250.
[2] WANG Y M, ZHU K F, ZHOU W J, et al.Sarcopenia is associated with the presence of nonalcoholic fatty liver disease in Zhejiang Province, China: a cross-sectional observational study[J]. BMC Geriatr, 2021, 21(1):55.
[3] GOLABI P, GERBER L, PAIK J M, et al.Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease[J]. JHEP Rep, 2020, 2(6):100171.
[4] KIM J A, CHOI K M.Sarcopenia and fatty liver disease[J]. Hepatol Int, 2019, 13(6):674-687.
[5] PHILLIPS T, LEEUWENBURGH C.Muscle fiber-specific apoptosis and TNF-α signaling in sarcopenia are attenuated by life-long calorie restriction[J]. FASEB J, 2005, 19(6):668-670.
[6] DE FRE C H, DE FRE M A, KWANTEN W J, et al.Sarcopenia in patients with nonalcoholic fatty liver disease: is it a clinically significant entity?[J]. Obes Rev, 2019, 20(2): 353-363.
[7] DZIK K P, KACZOR J J. Mechanisms of vitamin D on skeletal muscle function: oxidative stress, energy metabolism and anabolic state[J]. Eur J Appl Physiol, 2019, 119(4):825-839.
[8] GIRGIS C M, CHA K M, SO B, et al.Mice with myocyte deletion of vitamin D receptor have sarcopenia and impaired muscle function[J]. J Cachexia Sarcopenia Muscle, 2019, 10(6):1228-1240.
[9] GUO X, WANG C, YANG T, et al.Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials [J]. Food Funct, 2020, 11(9):7389-7399.
[10] LIU S, LIU Y, WAN B, et al.Association between vitamin D status and non-alcoholic fatty liver disease: a population-based study[J]. J Nutr Sci Vitaminol, 2019, 65(4):303-308.
[11] LEVITT D G, LEVITT M D. A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans[J].Clin Exp Gastroenter, 2018, 11:193-215.
[12] KUMAR A, DAVULURI G, SILVA R N, et al.Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis[J]. Hepatology, 2017, 65(6):2045-2058.
[13] HONG S, CHOI K M. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences[J]. Int J Mol Sci, 2020, 21(2):494.
[14] VISSER M, PAHOR M, TAAFFE D R, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC study[J]. J Gerontol A Biol Sci Med Sci, 2002, 57(5): M326-M332.
[15] CHAKRAVARTHY M V, SIDDIQUI M S, FORSGREN M F, et al.Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis[J]. Front Endocrinol: Lausanne, 2020, 11:592373.
[16] CAMPOREZ J P G, JORNAYVAZ F R, PETERSEN M C, et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice[J].Endocrinology, 2013, 154(9):3099-3109.
[17] GUSAROVA V, O'DUSHLAINE C, TESLOVICH T M,et al. Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes[J]. Nat Commun, 2018, 9(1):2252.
[18] DELOGU W, CALIGIURI A, PROVENZANO A, et al.Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation [J]. Dig Liver Dis, 2019, 51(10):1400-1408.
[19] AJAZ S, MCPHAIL M J, GNUDI L, et al.Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease(NAFLD)[J]. Mitochondrion, 2021, 57:119-130.
[20] ZHANG X, WONG G L, WONG V W S.Application of transient elastography in nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2020, 26(2):128-141.
[21] DAI H J, WANG W J, CHEN R F, et al. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults[J]. Nutr Metab, 2017, 14:49.
[22] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3):300-307.
[23] YU R, SHI Q W, LIU L, et al. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis[J]. BMC Gastroenterol, 2018, 18(1):51.
[24] MARTINEZ-ARNAU F M, FONFRIA-VIVAS R, BUIGUES C, et al.Effects of leucine administration in sarcopenia: a randomized and placebo-controlled clinical trial[J]. Nutrients, 2020, 12(4):932.
[25] ABENAVOLI L, BOCCUTO L, FEDERICO A, et al.Diet and non-alcoholic fatty liver disease: the Mediterranean way[J]. Int J Environ Res Public Health, 2019, 16(17):3011.
[26] JEGATHEESAN P, DE BANDT J P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism[J]. Nutrients, 2017, 9(3):230.
[27] PLAUTH M, BERNAL W, DASARATHY S, et al.ESPEN guideline on clinical nutrition in liver disease[J]. Clin Nutr, 2019, 38(2):485-521.
[28] KAWAO N, MORITA H, IEMURA S, et al. Roles of Dkk2 in the linkage from muscle to bone during mechanical unloading in mice[J]. Int J Mol Sci, 2020, 21(7):2547.
[29] CAREY E J, LAI J C, SONNENDAY C, et al. A North American expert opinion statement on sarcopenia in liver transplantation[J]. Hepatology, 2019, 70(5):1816-1829.
[30] BUTTERWORTH R F, CANBAY A. Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease[J]. Dig Dis, 2019, 37(1):63-68.
[31] JAKOVLJEVIC D G, HALLSWORTH K, ZALEWSKI P, et al. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease[J]. Clin Sci, 2013, 125(3):143-149.
[32] ROMERO-GOME M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4):829-846.
[33] KEATING S E, HACKETT D A, GEORGE J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. J Hepatol, 2012, 57(1):157-166. |
